Closing Bell Manifest Space: Varda Closes $187 Million Series C Round with Varda Space CEO Will Bruey 7/11/25
Jul 11, 2025
In this discussion, Will Bruey, Co-founder and CEO of Varda Space, shares insights on the groundbreaking work of his in-space manufacturing startup. He delves into the revolutionary potential of drug manufacturing in microgravity, showcasing its ability to enhance drug formulations. Bruey also highlights advancements in reusable rocket technology and hypersonic testing for the Department of Defense, revealing how these innovations are transforming pharmaceutical production and testing in extreme environments.
AI Snips
Chapters
Transcript
Episode notes
Microgravity Enables Novel Drug Forms
- Varda Space uses microgravity in orbit to manufacture drug formulations otherwise impossible on Earth.
- Removing gravity allows novel drug forms, enhancing patient experience and therapeutic options.
Space Launch as High-Value Shipping
- Varda shares rides on rockets to reduce launch cost, viewing launches as just high-value shipping.
- Their reentry capsule preserves unique microgravity drug properties for delivery back to pharma labs.
Ritonavir Mission Demonstrates Value
- Varda flew the HIV drug ritonavir on their first mission, once recalled due to crystal form issues.
- This proved Varda’s ability to prevent manufacturing issues by controlling crystallization in space.